ACE2 and type 2 diabetes mellitus: Patients with type 2 diabetes are characterized by an increased expression of ACE2 in the lungs [21], which is caused by chronic inflammation, endothelial cell activation, and insulin resistance that exacerbates the inflammatory response and leads to alveolar-capillary barrier dysfunction and could explain the severe COVID-19 prognosis in diabetic patients [22].